Pay in 4 interest-free payments of $5.29 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
These are completely different products with different mechanisms, different dosing, and different expectations
Importantly, most GLP-1 receptor agonists carry a boxed warning about the risk of thyroid C-cell tumors and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
many plans still exclude "weight loss" medications
( "" ), , ,
The 24.2% average weight loss seen with Retatrutide approaches the results typically achieved with bariatric surgery, which produces 25-30% weight loss
Because GLP-1 therapies significantly reduce appetite, many people eat less
US$ 27.24
US$ 22.81
US$ 23.11
US$ 24.16
US$ 22.73
US$ 29.80
US$ 22.31
